Report: U.K. biotech pulling ahead in Europe

Monday, July 27, 2015

Over the past 10 years, the U.K. biotech sector has outperformed other European countries, raising $1.4 billion via IPOs and $2.4 billion in venture capital, according to a new report from life science market intelligence firm Evaluate and the U.K. BioIndustry Association (BIA). The rise in optimism has been most evident in 2014, with the momentum continuing into 2015.

[Read More]

BIA responds to Jim O’Neill’s review on antimicrobial resistance

Monday, June 22, 2015

The U.K. Bioindustry Association (BIA) has submitted its initial response to Jim O’Neill’s review on antimicrobial resistance (AMR), focusing on his interim report Securing new drugs for future generations: The antibiotics pipeline, published in May. Steve Bates, CEO of the BIA, put forward the case that any new economic model should be based on an informed stewardship not restrictive stewardship approach.

[Read More]

Industry reacts to U.K. budget announcement

Thursday, March 20, 2014

Positive and negative industry responses have surfaced regarding Chancellor George Osborne’s budget, from the Ethical Medicines Industry Group (EMIG), the BioIndustry Association (BIA) and the Royal College of General Practitioners (RCGP). The budget includes a $90.9 million establishment of a large-scale cell therapy manufacturing center, an increase in the R&D Tax Credit from 11% to 14.5%, and $175.1 million over five years for doctoral training centers.

[Read More]

BIA comments on Fresh Start report

Friday, January 17, 2014

Commenting on the Fresh Start report on the E.U. impact on the U.K. life science sector, Steve Bates, CEO of the BioIndustry Association (BIA), a trade association for innovative enterprises involved in U.K. bioscience, said, “This well researched report by George Freeman is right to point out that the E.U. is seen as an enlightened and progressive region for investing in biomedical research and that E.U. membership gives U.K.-based life science companies access to the single market and a uniform regulatory system for the development and approval of therapies.

[Read More]

BIA says E.U. Clinical Trial Regulation misses goal to make E.U. more attractive for trial conduct

Thursday, January 2, 2014

The endorsement by the E.U. Committee of Permanent Representatives of the political agreement reached by the Lithuanian E.U. Council Presidency and the European Parliament, on the compromise text of the proposed E.U. Clinical Trials Regulation looks set to not deliver on the initial goal set by the European Commission (E.C.) when it launched the process in July 2012 of making the E.U. a more attractive location to conduct clinical trials.

[Read More]